Company OverviewArtelo Biosciences
Artelo Biosciences, Inc. (NASDAQ:ARTL) is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system.
Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.
Speaker BioPresident & CEO
Artelo Biosciences
Gregory D. Gorgas has served as Artelo’s President, Chief Executive Officer and on the board of directors since April 2017. He holds three decades of successful drug development and commercialization experience in both pharmaceutical corporations and biotech companies, including more than a dozen product launches, four of which were first-in-class.
Before leading Artelo, Mr. Gorgas served as Senior Vice President, Commercial and corporate officer at Mast Therapeutics, a publicly held biotechnology company, where he had commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular programs.
Prior to that, Mr. Gorgas worked at Biogen, a publicly held biotechnology company, as Senior Director, Global Marketing with responsibility for the strategic vision and operational commercialization of the company’s worldwide cancer business.
Previously he held leadership positions of increasing responsibility with IDEC Pharmaceuticals, Chiron, Cetus and Upjohn, all publicly held companies. Mr. Gorgas currently serves as member of the board of directors at Theragence and on the advisory board of Klotho Therapeutics. Mr. Gorgas earned a BA in economics from California State University, Northridge and, from the University of Phoenix, an MBA.
